Table 3.
Prevalence of Recurrence, Metastases, and Secondary Cancers of Prostate Cancer Patients with Metformin Versus Controls
| Variable | Non-Metformin n = 149 % |
Metformin n = 84a % |
Cramer’s V | p-value |
|---|---|---|---|---|
| Cancer-related outcomes | 31.5 | 14.3 | .191 | .004 |
| Recurrences | 14.8 | 8.3 | .094 | .153 |
| Metastases | 4.7 | 0 | .132 | .051 |
| Secondary cancers | 17.4 | 6.0 | .163 | .013 |
Note: Cancer-related outcomes = presence of Recurrences, Metastases, and/or Secondary cancers
a
Only patients that stayed on metformin during the entire course of their prostate cancer were assessed for cancer-related outcomes